NCR Online Journal

Hepatitis B Virus Pipeline Assessment 2022 report covers Unmet Needs, Key Opportunities, and Major Players by DelveInsight

 Breaking News
  • No posts were found

Hepatitis B Virus Pipeline Assessment 2022 report covers Unmet Needs, Key Opportunities, and Major Players by DelveInsight

July 22
22:11 2022
Hepatitis B Virus Pipeline Assessment 2022 report covers Unmet Needs, Key Opportunities, and Major Players by DelveInsight
Hepatitis B Virus Pipeline

DelveInsight highlights recent progress and expected entry of Hepatitis B Virus emerging therapies, including all phases of drug developments 

DelveInsight’s “Hepatitis B Virus Pipeline Insight” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hepatitis B Virus pipeline landscape. It comprises Hepatitis B Virus pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Hepatitis B Virus therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Hepatitis B Virus pipeline products.   

 

Some of the significant Hepatitis B Virus Pipeline Report Highlights 

  • Key players that are developing the drugs for the treatment of Hepatitis B Virus include Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Nucorion Pharmaceuticals, Gilead Sciences, Dong-A ST Co., Assembly Biosciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals and Others
  • In September 2019, Xi’an Xintong Medicine Research (Chinese license) reported positive results from a Phase II trial of pradefovir, showing good efficacy, safety and tolerability. At the dose of 75 mg, the reduction of DNA viral load, the percentage of no viral load detected, and HBeAg negative conversion rate were better than tenofovir disoproxil fumarate (TDF) after 24 weeks of treatment. Overall incidence of side effects was less than TDF and there was no renal or skeletal toxicity.
  • Some of the Hepatitis B Virus Market Drivers are High prevalence of chronic HBV infection and rising case of liver cancer and cirrhosis deaths due to HBV infection.

 

Request for sample pages @ Hepatitis B Virus Pipeline Overview

 

Hepatitis B virus is a small DNA virus that belongs to the “Hepadnaviridae” family. It is a vaccine-preventable liver infection caused by the HBV. A hepatitis B infection can result in either an acute infection or a chronic infection. When a person is first infected with the hepatitis B virus, it is called an “acute infection” and most healthy adults that are infected do not have any symptoms and are able to get rid of the virus without any problems. Moreover, some adults are unable to get rid of the virus after six months are diagnosed with “chronic infection.“ In this condition, the immune system is not able to get rid of the hepatitis B virus and it still remains in their blood and liver.

 

Hepatitis B Virus Pipeline Therapeutics

Pradefovir: Ligand Pharmaceuticals

Pradefovir, an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir is currently under development for the treatment of chronic HBV infection. The drug is developing using Ligand’s HepDirect technology.

VIR 2218: Vir Biotechnology

VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.

ABI H3733: Assembly Biosciences

ABI-H3733 (3733), is an investigational next-generation, highly potent core inhibitor. 3733 has demonstrated significantly increased potency against covalently closed circular DNA (cccDNA) formation and new virus production as compared to first-generation core inhibitors in preclinical studies. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Chronic Hepatitis B virus Infection.

 

For further product profiles, request @ Hepatitis B Virus Pipeline Landscape 

 

Scope of Hepatitis B Virus Pipeline Drug Insight  

  • Coverage: Global 
  • Major Players: 80+ Key Players
  • Prominent Players: Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Nucorion Pharmaceuticals, Gilead Sciences, Dong-A ST Co., Assembly Biosciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals and Others, and many others.  
  • Key Drugs Profiles: 80+ Products
  • Phases:  
    • Hepatitis B Virus Therapies Late-stage (Phase III)  
    • Hepatitis B Virus Therapies (Phase II)
    • Hepatitis B Virus Therapies (Phase I) 
    • Hepatitis B Virus Therapies Pre-clinical stage and Discovery candidates 
    • Discontinued and Inactive candidates 
  • Molecule Types:  
    • Small molecule
    • Gene therapy  
    • Stem cell therapy  
  • Mechanism of Action:
    • Protease inhibitors 
    • Immunomodulatory 
    • And Others
  • Route of Administration:
    • Oral
    • Inhalation 
    • Subcutaneous 
    • Intravenous
  • Product Types:
    • Monotherapy
    • Combination 

 

To get free access to Sample Report: https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight

 

Key Questions regarding Current Hepatitis B Virus Treatment Landscape and Emerging Therapies Answered in the Pipeline Report    

  • What are the current options for Hepatitis B Virus treatment?
  • How many companies are developing therapies for the treatment of Hepatitis B Virus? 
  • How many Hepatitis B Virus emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Hepatitis B Virus?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Hepatitis B Virus market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Hepatitis B Virus?  
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Hepatitis B Virus therapies? 
  • What are the key designations that have been granted for the emerging therapies for Hepatitis B Virus? 
  • How many patents are granted and pending for the emerging therapies for the treatment of Hepatitis B Virus?

 

To get free access to Sample Report: https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight

 

Table of Contents

1. Hepatitis B Virus Introduction

2. Hepatitis B Virus Executive Summary

3. Hepatitis B Virus Overview

4. Hepatitis B Virus Analytical Perspective In-depth Commercial Assessment

5. Hepatitis B Virus Pipeline Therapeutics

5.1. Hepatitis B Virus Late Stage Products (Phase III)

5.2. Hepatitis B Virus Mid Stage Products (Phase II)

5.3. Hepatitis B Virus Early Stage Products (Phase I/II)

5.4. Early Stage Products (Phase I)

6. Hepatitis B Virus Therapeutic Assessment

7. Hepatitis B Virus Inactive Products

8. Company-University Collaborations (Licensing/Partnering) Hepatitis B Virus Analysis

9. Hepatitis B Virus Key Companies

10. Hepatitis B Virus Key Products

11 . Hepatitis B Virus Unmet Needs

12. Hepatitis B Virus Market Drivers and Barriers

13. Hepatitis B Virus Future Perspectives and Conclusion

14. Hepatitis B Virus Analyst Views

15. Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-pipeline-insight

Related Articles